文献速递外周动脉疾病

中段股腘动脉TASC II B/C病变:PTA/支架与旁路手术的成本效果比较

A Comparative Cost-Effectiveness Analysis of Percutaneous Transluminal Angioplasty With Optional Stenting and Femoropopliteal Bypass Surgery for Medium-Length TASC II B and C Femoropopliteal Lesions.
PubMed 文献 · J Endovasc Ther · 2019-01-01

本研究纳入226例中段股腘动脉TASC II B/C病变患者,比较经皮腔内血管成形术联合选择性支架(PTA/S)与股腘动脉旁路术(FPB)的3年总费用和成本效果。PTA/S组平均总费用为€29,058,FPB组为€42,437(调整后平均差-€14,820,95%CI -€29,044至-€5,976),3年一期通畅率差异无统计学意义(68.9% vs 70.3%),ICER为563,716。结论推荐Endovascular-first策略以最小化费用。

要点

  • PTA/S组3年总费用显著低于FPB组(€29,058 vs €42,437)
  • 两组3年一期通畅率无显著差异(68.9% vs 70.3%)
  • 中段股腘动脉病变推荐Endovascular-first策略以降低费用

核心结论

  • 对于中段股腘动脉TASC II B/C病变,FPB在3年随访期内总费用更高,推荐Endovascular-first策略以实现费用最小化。

主要发现

  • PTA/S组平均总费用€29,058,FPB组€42,437,调整后平均差-€14,820(95%CI -€29,044至-€5,976)。
  • 3年一期通畅率PTA/S组68.9%,FPB组70.3%,差异无统计学意义。
  • ICER为563,716,即FPB相比PTA/S每多获得一例3年一期通畅患者需多花费€563,716。

关键数值与推荐

  • PTA/S组135例(平均年龄69.9±10.9岁,83例男性),其中TASC B 108例(63.5%),TASC C 27例(48.2%)。

临床怎么用

  • 在中段股腘动脉TASC II B/C病变的治疗决策中,可优先考虑PTA/S以降低中期总费用,同时不牺牲3年一期通畅率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the total midterm costs and cost-effectiveness of percutaneous transluminal angioplasty with optional stenting (PTA/S) as initial treatment compared with femoropopliteal bypass (FPB) surgery in patients with medium-length TransAtlantic Inter-Society Consensus II (TASC) B and C femoropopliteal lesions. MATERIALS AND METHODS: Over a period of 3 years, all hospital health care costs for 226 consecutive patients were calculated: 170 patients with a TASC B lesion and 56 patients with a TASC C lesion. In the 135-patient PTA/S group (mean age 69.9±10.9 years; 83 men), 108 (63.5%) patients had TASC B lesions and 27 (48.2%) patients had TASC C lesions. Ninety-one patients (mean age 68.4±10.9 years; 60 men) were treated with FPB for 62 TASC B and 29 TASC C femoropopliteal lesions. The main outcome measure was the primary patency rate at 3-year follow-up. Multiple imputation and bootstrapping techniques were used to analyze the data. The adjusted incremental cost-effectiveness ratios (ICERs) were calculated by dividing the difference in total costs by the difference in 3-year primary patency rate. Costs were expressed in euros (€), and cost differences are presented with the 95% confidence interval (CI). RESULTS: Mean total costs per patient were €29,058 in the PTA/S treatment group vs €42,437 in the FPB group (mean adjusted difference -€14,820, 95% CI -€29,044 to -€5976). Differences in 3-year primary patency between PTA/S and FPB were small and nonsignificant (68.9% and 70.3%, respectively). An ICER of 563,716 was found, indicating that FPB costs €563,716 more per one extra patient reaching 3-year primary patency in comparison with PTA/S treatment. CONCLUSION: FPB in medium-length femoropopliteal lesions involved higher total costs when evaluated over a 3-year follow-up period. An endovascular-first approach is recommended, as this will result in cost minimization for patients with medium-length femoropopliteal disease.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Vossen RJ, Philipszoon PC, Vahl AC, et al. A Comparative Cost-Effectiveness Analysis of Percutaneous Transluminal Angioplasty With Optional Stenting and Femoropopliteal Bypass Surgery for Medium-Length TASC II B and C Femoropopliteal Lesions. J Endovasc Ther. 2019. PMID: 30898070. doi:10.1177/1526602819833646

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。